Shortly, numerous clinical studies will be necessary to validate the therapeutic benefits of phytochemicals that target NLRP3 in treating IBD due to the elevated prices of synthetic medicines and their deleterious adverse events [104,105,106]. This evidence concerns the gene NLRP3 and inflammatory bowel disease.